Get the Daily Brief
Latest Biotech News
Parse and Graph partner to build immune perturbation atlas – scale and context for AI drug discovery
Parse Biosciences and Graph Therapeutics announced a strategic collaboration to create a large, functional immune perturbation atlas profiling hundreds of millions of human cells. The program will...
Insilico inks $120M pact with Qilu — AI‑powered cardiometabolic discovery deal
Insilico Medicine signed a collaboration with Shanghai’s Qilu Pharmaceutical worth up to $120 million to discover small molecules for cardiometabolic diseases using Insilico’s AI drug‑discovery...
Altido Bio raises seed to commercialize MGH CAR‑T for glioblastoma – early tumor shrinkage seen
Altido Bio closed a $12.5 million seed round led by ARCH Venture Partners to advance a CAR‑T therapy developed at Massachusetts General Hospital for glioblastoma. The startup, led by industry...
TRexBio extends Series B with $50M — funds Treg‑activating programs into the clinic
TRexBio secured an additional $50 million in a Series B extension to advance TRB‑061 and other Treg‑focused programs toward human testing. The financing will support Phase 1 work in atopic...
10x Genomics pushes into clinical diagnostics – CLIA lab, hospital partnerships in motion
10x Genomics announced clinical collaborations with Brigham & Women’s Hospital, Dana‑Farber Cancer Institute and the Cancer Research Institute and committed to build a CLIA‑certified laboratory to...
Oxford Nanopore reverses P2 Solo sunset – support extended to 2030 after backlash
Oxford Nanopore Technologies extended support for its PromethIon 2 Solo (P2 Solo) sequencer through the end of 2030 after strong customer criticism of an earlier discontinuation plan. The company...
CMS Adds 15 Drugs for IRA Price Talks — $27B at Stake
The Centers for Medicare & Medicaid Services on Jan. 27 identified 15 high-spend medicines for the next round of price negotiations under the Inflation Reduction Act. The list includes inhalers,...
FDA Greenlights Reprogramming Trial: Life Biosciences to Test ER‑100
The FDA has allowed Life Biosciences to begin the first human study of an epigenetic “reprogramming” gene therapy, enrolling a small cohort of glaucoma patients under the ER‑100 program. The trial...
Roche Pushes CT‑388 to Phase 3 — 22.5% Placebo‑Adjusted Weight Loss
Roche reported mid‑stage results for CT‑388, a dual GLP‑1/GIP receptor agonist, showing about 22.5% placebo‑adjusted weight loss at 48 weeks in a ~469‑patient Phase 2 study and signaled plans to...
FDA Lifts Hold on One Intellia CRISPR Trial — Cardiac Study Remains Paused
Regulators lifted the clinical hold on Intellia’s Magnitude‑2 Phase 3 trial of its CRISPR/Cas9 therapy for transthyretin amyloidosis with polyneuropathy (ATTR‑PN) while the sibling Magnitude study...
Oxford Nanopore Reverses Course — P2 Solo Supported Through 2030
Oxford Nanopore extended hardware and software support for its PromethIon 2 Solo (P2 Solo) sequencer through the end of 2030 after widespread customer backlash to an earlier phase‑out plan. The...
nRichDx and Hamilton Automate Liquid‑Biopsy Workflow — Wash & Elute Now Integrated
nRichDx and Hamilton advanced a commercial automation partnership to complete the Revolution Plus sample‑prep workflow for liquid biopsy on the Hamilton Microlab STAR platform, integrating the...
Eclipsebio Acquires Terrain Bio — Assembles RNA Design‑to‑Manufacturing Stack
Eclipsebio acquired Terrain Bio to combine Terrain’s machine‑learning RNA design capabilities with Eclipsebio’s sequencing‑first analytics, aiming to build an end‑to‑end RNA therapeutic design,...
TRexBio Nets $50M Extension to Advance Treg Programs — TRB‑061 in Phase 1
TRexBio closed a $50 million Series B extension to fund clinical development of Treg‑activating candidates, including TRB‑061 for atopic dermatitis, and to advance two additional programs into...
Genmab Halts Enrollment in Early‑Stage Trial of ProfoundBio Asset
Genmab stopped enrollment in a Phase 1/2 study of GEN1286, an oncology candidate it acquired through its $1.8 billion ProfoundBio buyout, pausing progress of the early‑stage program as the company...
Alphamab’s HER2 Bispecific Cuts Progression Risk 75% in Phase 3
Suzhou‑based Alphamab reported Phase 3 KC‑Wise results showing its HER2 bispecific antibody anbenitamab (KN‑026) plus chemotherapy reduced progression risk by 75% in patients with HER2‑positive...
CMS names 15 drugs for IRA price talks — new prices due 2028
The Centers for Medicare & Medicaid Services unveiled the next cohort of 15 high-spend medicines selected for price negotiations under the Inflation Reduction Act. CMS named brands across multiple...
FDA lifts hold on one Intellia CRISPR trial — Magnitude‑2 cleared to resume
The U.S. Food and Drug Administration has lifted a clinical hold on Intellia Therapeutics’ Magnitude‑2 Phase 3 trial of its CRISPR/Cas9 therapy nexiguran ziclumeran (nex‑z) for transthyretin...
Roche posts competitive Phase 2 weight loss — CT‑388 headed to Phase 3
Roche reported Phase 2 data showing its dual GLP‑1/GIP agonist CT‑388 produced approximately 22.5% placebo‑adjusted weight loss at 48 weeks, prompting the company to progress the asset into Phase...
TRexBio raises $50M extension — funds Treg‑targeted eczema program
TRexBio closed a $50 million extension of its Series B to accelerate clinical testing of its Treg‑activating immunotherapies, including lead candidate TRB‑061 for atopic dermatitis. The financing...